Sulfatinib - Hutchison MediPharma

Drug Profile

Sulfatinib - Hutchison MediPharma

Alternative Names: HMPL-012; Sufatinib

Latest Information Update: 06 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hutchison MediPharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Macrophage colony stimulating factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Neuroendocrine tumours
  • Phase II Biliary cancer; Thyroid cancer
  • Phase I Solid tumours

Most Recent Events

  • 06 Aug 2018 Chemical structure information added
  • 23 Jul 2018 Phase-I/II clinical trials in Biliary cancer (Second-line therapy or greater, Late-stage disease) in USA (PO)
  • 23 Jul 2018 Phase-I/II clinical trials in Neuroendocrine tumours (Late-stage disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top